Regencell Bioscience Lim... (RGC)
Regencell Bioscience Limited (RGC) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | 4.38 |
| Marktkapitalisierung | 2.93 Mrd |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -7.05 Mio |
| Beta | 1.49 |
| EPS (ttm) | -0.01 |
| KGV (TTM) | n/a |
| Forward-KGV | n/a |
| KBV (TTM) | 2960.00 |
| KUV (TTM) | n/a |
| Earnings Date | Jul 16, 2025 |
| Brief | 7.1 |
| Volumen | 220,443 |
| Ø Vol. (20D) | 302,506 |
| Eröffnung | 5.42 |
| Vortagesschluss | 5.46 |
| Tagesspanne | 5.42 - 6.10 |
| 52-Wk Range | 4.51 - 69.00 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über RGC
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong....
Vollständiges UnternehmensprofilFinanzielle Entwicklung
Im Jahr 2024 betrug der Umsatz von Regencell Bioscience 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -4.3 Mio, ein Rückgang von -26.73 %.
FinanzberichteAnalysten erwarten einen Umsatz von ... Upgrade
vor 3 Monaten · Simply Wall St.
Auditor Change Puts Regencell Bioscience Governance And Cash Runway In FocusRegencell Bioscience Holdings (NasdaqCM:RGC) has changed its independent auditor. The company disclosed the auditor replacement as a material corporate governance event. The change could affect how Re...
